The U.S. Food and Drug Administration agreed Tuesday to loosen restrictions on the way Vivus' Qsymia can be prescribed, allowing the weight-loss pill Qsymia to be dispensed from retail pharmacies. When approved last year, FDA restricted the drug's distribution to mail-order pharmacies due to concerns about the risk of birth defects.
Vivus has blamed Qsymia's disappointing launch, in part, on the mail-order pharmacy restriction. Sales totaled $2 million in the fourth quarter, well below investor expectations.
"Our goal over the next three months is to ensure availability of Qsymia in thousands of certified retail pharmacies nationwide," said Vivus President Peter Tam, in a statement. "The REMS modification is a key accomplishment in removing a major barrier that has hindered the initial acceptance of Qsymia into everyday medical practice. We believe that retail access, along with ongoing improvements in reimbursement, will help to accelerate Qsymia awareness, trial and usage."Vivus shares spiked above $12 per share when the Qsymia announcement hit the tape Tuesday afternoon but shares are now trading up 5% to $11.70. Arena Pharmaceuticals (ARNA), which hopes to compete against Vivus with its own obesity pill Belviq, has been waiting nine and half months for DEA to finalize scheduling. -- Reported by Adam Feuerstein in Boston. Follow @AdamFeuerstein
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV